Stories
Jagsonpal Pharmaceuticals Acquires Group Pharma's Wellness Portfolio for ₹47 Crore
C
CNBC TV18•23-09-2026, 18:59
Jagsonpal Pharmaceuticals Acquires Group Pharma's Wellness Portfolio for ₹47 Crore
- •Jagsonpal Pharmaceuticals Ltd announced the acquisition of Group Pharmaceuticals Ltd's wellness portfolio for up to ₹46.7 crore through a slump sale.
- •The transaction involves an initial payment of ₹23.7 crore at closing, with an additional ₹23 crore contingent on FY2027-28 sales, capped at ₹46.7 crore.
- •The acquisition, expected to finalize by November 1, 2026, will strengthen Jagsonpal's pharmaceutical portfolio and expand its market reach, particularly in women's healthcare.
- •The wellness portfolio recorded a turnover of ₹24.6 crore in FY2025-26 and includes identified products, assets, contracts, and employees.
- •Jagsonpal intends to integrate the acquired portfolio with its existing commercial platform and leverage its distribution network to create operating synergies.
Key Questions Answered
Jagsonpal Pharmaceuticals is acquiring Group Pharmaceuticals' wellness portfolio for a total consideration of up to ₹46.7 crore through a slump sale. The transaction includes an initial consideration of ₹23.7 crore on closing, along with up to ₹23 crore linked to FY2027-28 sales.
The acquisition is expected to be completed on or before November 1, 2026, subject to the fulfilment of conditions precedent and other terms outlined in the Business Transfer Agreement.
The wellness portfolio recorded a turnover of ₹24.6 crore during the 2025-26 financial year.
